Israel’s Nervomatrix has reported success from independent controlled trials of its hyper-stimulation pulse device for treating lower back pain. The study on 28 patients at Belgian’s Free University of Brussels obtained significant pain relief after 4 treatments compared to a … Continue reading →

The US FDA has given fast track approval to Israel’s BioBlast for its Cabaletta treatment for two rare and currently untreatable conditions – oculopharyngeal muscular dystrophy (OPMD) and spinocerebellar ataxia type 3 (SCA3). http://www.israel21c.org/drug-for-rare-muscular-dystrophy-fast-tracked/

Israel’s BiondVax has published independent tests of trials showing that its M-001 Universal Flu vaccinations given 3 years ago have protected patients from flu strains that only came into existence well after the vaccine was administered. http://www.biondvax.com/2015/08/03/independent-results-show-that-biondvaxs-universal-flu-vaccine-administered-in-a-trial-3-years-ago-improves-immunogenicity-against-current-flu-h3n2-epidemic/

Israel’s LifeBond has developed LifeSeal (see Aug 2011 newsletter) – a sealant to greatly reduce surgical leaks, which are associated with potential infections and other serious complications, risking the lives of hundreds of thousands every year. LifeBond has just raised … Continue reading →

Three Israeli companies were chosen by the World Economic Forum (WEF) in its 2015 list of 14 Technology Pioneers in the Life Science and Health category. ElMindA’s Brain Network Activation identifies brain damage. Consumer Physics’s SCIO is a chemical analyzer. … Continue reading →

Israeli startup XACT Robotics developed a robotic system for needle steering, for use in biopsies and ablations, or to inject medications in specific areas of the body. The first application of XACT’s technology will be for biopsies in lung tissue. … Continue reading →